MAPK-IN-2

• Target :

  CDK|||p38 MAPK|||c-Met/HGFR|||Raf|||EGFR

• Related Pathways :

  MAPK|||Cell Cycle/Checkpoint|||Angiogenesis|||Tyrosine Kinase/Adaptors|||JAK/STAT signaling

• Bioactivity :

  MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell lines. It demonstrates robust suppression of the MAPK pathway (EGFR WT IC50 = 281 nM, c-MET IC50 = 205 nM, B-RAF WT IC50 = 112 nM, CDK4/6 IC50 = 95 and 184 nM, respectively) and exhibits pronounced activity against mutated forms of EGFR and B-RAF (EGFR T790M IC50 = 69 nM and B-RAF V600E IC50 = 83 nM) [1].

• Smiles :

  ClC1=CC=C(C(C=C(C2=CNC3=C2C=CC=C3)N4)=C(C#N)C4=O)C(Cl)=C1

• Molecular Formula :

  C20H11Cl2N3O

• Molecular Weight :

  380.23

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C